Broker research reports for stocks which have been downgraded by brokers. Both recommendation downgrades,
as well as share price target downgrades are available .
Broker Research reports: latest Downgrades
for all stocks
headwinds and lower ARV sales, while US sales improved QoQ. Sustainability of current run-rate of US sales is key, which hinges on timely niche approvals along with stabilisation of pricing pressure in base business. ARBP has multiple growth drivers in place with investments in vaccines, injectables, biosimilars and API, which are expected to be reflected from H2FY23. In near term, cost headwinds will continue to drag profitability. At CMP, stock is...
Downgrade the stock to HOLD (BUY earlier) with revised TP of Rs. 3,775 (Rs. 3,890 earlier) valuing it at 43x PE its FY24E. Key downside risks to our estimates continued surge in RM prices, emergence of 3rd COVID wave impacting demand.
We maintain our HOLD rating given the delay in the ROE normalization, higher restructured pool with concerns of elevated slippages especially from the MFI pool and asset quality concerns (primarily in the MFI book). We introduce FY24E estimates and value UJSFB at 1.4x H1FY24E ABV to arrive at a targ
Considering overall increase in competition and persisting price erosion in the US market (68% revenue in the US) and higher frequency of USFDA inspection may lead to more surprise in number in upcoming quarters. Therefore, we recommend HOLD rating on the stock with Target Price of Rs 740/share.
Well-diversified order backlog, robust execution capabilities, proficient management and strong focus on debt reduction and working capital are expected to outline NCC over the next few years Q2FY22 Results: NCC's Q2FY22 performance was on expected lines - strong...
Company is expected to fare well on the back drop of continued growth in revenue along with innovation of new drugs and medications. Hence, we reiterate our BUY rating on the stock with a revised target price of Rs. 5,437 using a target multiple of 23x FY23E adj. EPS. Topline aided by new Medications Q2FY22 revenue grew 17.8% YoY to Rs. 5,787cr, driven by significant growth in Global Generics segment (+19.0% YoY to Rs. 4,747cr) and robust performance from Proprietary Products segment (Rs. 123cr vs Rs. 10cr in Q2FY21, on the account of...
We are cutting our FY22/23/24 EPS estimates by 8.5%/4.5%/2.5% on account of 1) near term margin pressure on the back of unprecedented inflation and 2) volume pressure due to grammage reduction in price pointed packs (2/3 rd of portfolio). We believe that the margins are near bottom and expect QoQ...
MRFs sales grew weaker than peers due to weakness in TBB & Farm MRF's 2QFY22 performance was impacted by RM cost inflation and higher other cost. MRF lagged peers in revenue growth due to weaker performance of TBB and farm segment. The industry is taking gradual price increases to dilute impact of severe cost inflation. We cut our FY22E/FY23E EPS by ~29%/14% to factor in for RM cost inflation and higher other expenses. Maintain Neutral....
Aurobindo Pharma (ARBP)'s 2QFY22 results came in below our estimates, weighed by decline in ARV/API sales and an increase in raw material (RM) costs, which impacted profitability. Compared with the steady-to-declining...
About the stock: Pfizer collectively addresses 15 therapy areas with a portfolio of over 150 products that include therapeutics & vaccines. The company has been continuously restructuring its portfolio in the last few years to improve the...
